The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors

Azin Nezami, Ernesto I Freire

Research output: Contribution to journalArticle

Abstract

The plasmepsins are key enzymes in the life cycle of the Plasmodium parasites responsible for malaria. Since plasmepsin inhibition leads to parasite death, these enzymes have been acknowledged to be important targets for the development of new antimalarial drugs. The development of effective plasmepsin inhibitors, however, is compounded by their genomic diversity which gives rise not to a unique target for drug development but to a family of closely related targets. Successful drugs will have to inhibit not one but several related enzymes with high affinity. Structure-based drug design against heterogeneous targets requires a departure from the classic 'lock-and-key' paradigm that leads to the development of conformationally constrained molecules aimed at a single target. Drug molecules designed along those principles are usually rigid and unable to adapt to target variations arising from naturally occurring genetic polymorphisms or drug-induced resistant mutations. Heterogeneous targets need adaptive drug molecules, characterised by the presence of flexible elements at specific locations that sustain a viable binding affinity against existing or expected polymorphisms. Adaptive ligands have characteristic thermodynamic signatures that distinguish them from their rigid counterparts. This realisation has led to the development of rigorous thermodynamic design guidelines that take advantage of correlations between the structure of lead compounds and the enthalpic and entropic components of the binding affinity. In this paper, we discuss the application of the thermodynamic approach to the development of high affinity (Ki ∼ pM) plasmepsin inhibitors. In particular, a family of allophenylnorstatine-based compounds is evaluated for their potential to inhibit a wide spectrum of plasmepsins.

Original languageEnglish (US)
Pages (from-to)1669-1676
Number of pages8
JournalInternational Journal for Parasitology
Volume32
Issue number13
DOIs
StatePublished - Dec 4 2002

Fingerprint

Thermodynamics
Pharmaceutical Preparations
Parasites
Enzymes
Plasmodium
Drug Design
Antimalarials
Genetic Polymorphisms
Life Cycle Stages
Malaria
plasmepsin
Guidelines
Ligands
Mutation

Keywords

  • Adaptive inhibitors
  • Amino acid polymorphisms
  • Genomics
  • Malaria
  • Plasmepsins
  • Plasmodium
  • Protease inhibitors

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Cite this

The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. / Nezami, Azin; Freire, Ernesto I.

In: International Journal for Parasitology, Vol. 32, No. 13, 04.12.2002, p. 1669-1676.

Research output: Contribution to journalArticle

@article{fc0a5b7c3f4742a1b7de37bb9b51e8ba,
title = "The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors",
abstract = "The plasmepsins are key enzymes in the life cycle of the Plasmodium parasites responsible for malaria. Since plasmepsin inhibition leads to parasite death, these enzymes have been acknowledged to be important targets for the development of new antimalarial drugs. The development of effective plasmepsin inhibitors, however, is compounded by their genomic diversity which gives rise not to a unique target for drug development but to a family of closely related targets. Successful drugs will have to inhibit not one but several related enzymes with high affinity. Structure-based drug design against heterogeneous targets requires a departure from the classic 'lock-and-key' paradigm that leads to the development of conformationally constrained molecules aimed at a single target. Drug molecules designed along those principles are usually rigid and unable to adapt to target variations arising from naturally occurring genetic polymorphisms or drug-induced resistant mutations. Heterogeneous targets need adaptive drug molecules, characterised by the presence of flexible elements at specific locations that sustain a viable binding affinity against existing or expected polymorphisms. Adaptive ligands have characteristic thermodynamic signatures that distinguish them from their rigid counterparts. This realisation has led to the development of rigorous thermodynamic design guidelines that take advantage of correlations between the structure of lead compounds and the enthalpic and entropic components of the binding affinity. In this paper, we discuss the application of the thermodynamic approach to the development of high affinity (Ki ∼ pM) plasmepsin inhibitors. In particular, a family of allophenylnorstatine-based compounds is evaluated for their potential to inhibit a wide spectrum of plasmepsins.",
keywords = "Adaptive inhibitors, Amino acid polymorphisms, Genomics, Malaria, Plasmepsins, Plasmodium, Protease inhibitors",
author = "Azin Nezami and Freire, {Ernesto I}",
year = "2002",
month = "12",
day = "4",
doi = "10.1016/S0020-7519(02)00196-0",
language = "English (US)",
volume = "32",
pages = "1669--1676",
journal = "International Journal for Parasitology",
issn = "0020-7519",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors

AU - Nezami, Azin

AU - Freire, Ernesto I

PY - 2002/12/4

Y1 - 2002/12/4

N2 - The plasmepsins are key enzymes in the life cycle of the Plasmodium parasites responsible for malaria. Since plasmepsin inhibition leads to parasite death, these enzymes have been acknowledged to be important targets for the development of new antimalarial drugs. The development of effective plasmepsin inhibitors, however, is compounded by their genomic diversity which gives rise not to a unique target for drug development but to a family of closely related targets. Successful drugs will have to inhibit not one but several related enzymes with high affinity. Structure-based drug design against heterogeneous targets requires a departure from the classic 'lock-and-key' paradigm that leads to the development of conformationally constrained molecules aimed at a single target. Drug molecules designed along those principles are usually rigid and unable to adapt to target variations arising from naturally occurring genetic polymorphisms or drug-induced resistant mutations. Heterogeneous targets need adaptive drug molecules, characterised by the presence of flexible elements at specific locations that sustain a viable binding affinity against existing or expected polymorphisms. Adaptive ligands have characteristic thermodynamic signatures that distinguish them from their rigid counterparts. This realisation has led to the development of rigorous thermodynamic design guidelines that take advantage of correlations between the structure of lead compounds and the enthalpic and entropic components of the binding affinity. In this paper, we discuss the application of the thermodynamic approach to the development of high affinity (Ki ∼ pM) plasmepsin inhibitors. In particular, a family of allophenylnorstatine-based compounds is evaluated for their potential to inhibit a wide spectrum of plasmepsins.

AB - The plasmepsins are key enzymes in the life cycle of the Plasmodium parasites responsible for malaria. Since plasmepsin inhibition leads to parasite death, these enzymes have been acknowledged to be important targets for the development of new antimalarial drugs. The development of effective plasmepsin inhibitors, however, is compounded by their genomic diversity which gives rise not to a unique target for drug development but to a family of closely related targets. Successful drugs will have to inhibit not one but several related enzymes with high affinity. Structure-based drug design against heterogeneous targets requires a departure from the classic 'lock-and-key' paradigm that leads to the development of conformationally constrained molecules aimed at a single target. Drug molecules designed along those principles are usually rigid and unable to adapt to target variations arising from naturally occurring genetic polymorphisms or drug-induced resistant mutations. Heterogeneous targets need adaptive drug molecules, characterised by the presence of flexible elements at specific locations that sustain a viable binding affinity against existing or expected polymorphisms. Adaptive ligands have characteristic thermodynamic signatures that distinguish them from their rigid counterparts. This realisation has led to the development of rigorous thermodynamic design guidelines that take advantage of correlations between the structure of lead compounds and the enthalpic and entropic components of the binding affinity. In this paper, we discuss the application of the thermodynamic approach to the development of high affinity (Ki ∼ pM) plasmepsin inhibitors. In particular, a family of allophenylnorstatine-based compounds is evaluated for their potential to inhibit a wide spectrum of plasmepsins.

KW - Adaptive inhibitors

KW - Amino acid polymorphisms

KW - Genomics

KW - Malaria

KW - Plasmepsins

KW - Plasmodium

KW - Protease inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0037021403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037021403&partnerID=8YFLogxK

U2 - 10.1016/S0020-7519(02)00196-0

DO - 10.1016/S0020-7519(02)00196-0

M3 - Article

C2 - 12435452

AN - SCOPUS:0037021403

VL - 32

SP - 1669

EP - 1676

JO - International Journal for Parasitology

JF - International Journal for Parasitology

SN - 0020-7519

IS - 13

ER -